Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Rosa Rodriguez-Monguio, PhD, MS

Photo of Rosa Rodriguez-Monguio, PhD, MS
Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Phone415-502-6029
Emailrosa.rodriguez-monguio@ucsf.edu
ORCID ORCID Icon0000-0002-5526-9395 Additional info
vCardDownload vCard
    Other Positions
    Title(s)Director, Medication Outcomes Center


    Collapse Biography 
    Collapse education and training
    University of BarcelonaPhD2001Health Economics - Summa Cum Laude
    Massachusetts College of Pharmacy and Health SciencesMS2016Clinical Research
    Coro Center for Civic Leadership ProgramsCert2018Managers Engagement Program
    Birkbeck, University of LondonCert2021The Manager's Toolkit: A Practical Guide to Managing People at Work
    UCSFCert2021Diversity, Equity, and Inclusion Champion Training
    Coro Center for Civic Leadership ProgramsCert2022Leadership Collaborative
    Collapse awards and honors
    UCSF, School of Pharmacy 2023Dean’s Apple Award in recognition to outstanding efforts and commitment to pharmacy education
    World Health Organization (WHO), Division of Antimicrobial Resistance. Quadripartite Technical Group2023Technical Advisor
    UCSF, School of Pharmacy 2021Excellence in Precepting Award
    UCSF, School of Pharmacy2020Dean's Apple Award in recognition to outstanding efforts and commitment to pharmacy education
    Orphanet Journal of Rare Diseases2019Editorial Board
    BMC Health Services Research2019Editorial Board
    UCSF, School of Pharmacy2019Dean’s Apple Award in recognition to outstanding efforts and commitment to pharmacy education
    BMC Public Health2017Editorial Board
    Journal of Mental Health and Addiction2016  - 2017Editorial Board

    Collapse Overview 
    Collapse Global Health Equity
    Collapse Academic Senate

    Collapse Research 
    Collapse research activities and funding
    Advanced Therapy Medicinal Products: Clinical and Patient-Centered Outcomes
    Laura and John Arnold Foundation 25-14625Sep 1, 2025 - Aug 31, 2027
    Role: PI
    Description: Advanced Therapy Medicinal Products (ATMPs), including gene and cell therapies, have the potential to significantly improve outcomes for patients with severe and life-threatening conditions lacking effective treatments. The number of FDA-approved ATMPs is rapidly increasing, with nine new approvals in 2024 alone. There is an urgent need to systematically evaluate the approval pathways and therapeutic value of ATMPs to advance patient-centered outcomes. The specific aims of this study are (1) To assess the impact of federal policies in incentivizing the development and approval of ATMP improving outcomes for patients with unmet medical needs, and (2) To develop a decision-making algorithm to inform regulatory approvals, designations, and post-marketing requirements. Study findings will generate insights to optimize regulatory oversight and support the development of these high-impact, high-cost therapies ATMPs to improve health for populations with severe and life-threatening conditions.
    Real-World Effectiveness of Structured Diabetes Prevention Programs
    Centers for Disease Control and Prevention -CDC U18DP006708-01-00Sep 1, 2022 - Aug 31, 2027
    Role: Site PI
    Description: In 2011, the CDC launched the National Diabetes Prevention Program (DPP) to promote real-world implementation of the DPP lifestyle intervention. However, the long-term effectiveness and cost-effectiveness of the DPP in diverse healthcare settings are not well understood. In this study, we will evaluate DPP delivery across a multi-campus academic healthcare system and a three-state regional health network by triangulating electronic health record, insurance claims, and DPP cohort data. The Specific Aims are to: (1) create a longitudinal, multi-regional cohort of adults at risk for type 2 diabetes who enrolled in DPP and matched controls who did not; (2) assess the long-term effectiveness and cost-effectiveness of DPP, including cost per case of diabetes prevented and quality-adjusted life years (QALYs) gained; and (3) identify barriers and facilitators to DPP participation through targeted, representative surveys. Sensitivity analyses will examine variation in outcomes by delivery mode, social determinants of health, age, and race/ethnicity. Study findings will inform scalable, cost-effective strategies to prevent type 2 diabetes and support dissemination of effective models across healthcare systems, academic medical centers, and employer-based programs.
    A New Paradigm for Antibiotics Value-Based Innovation: Addressing Patient's Unmet Medical Needs
    Laura and John Arnold Foundation GR-65033Mar 1, 2022 - Jan 31, 2025
    Role: PI
    Description: Since the early 1990s, federal legislation—including the Prescription Drug User Fee Act (PDUFA, 1992), the FDA Modernization Act (1997), and the Biologics Price Competition and Innovation Act (2010)—has aimed to accelerate drug development and streamline FDA review. Our prior work found that PDUFA and Safety and Innovation Act (FDASIA, 2012) were associated with increased drug approvals and greater reliance on expedited approval pathways. However, it remains unclear whether the new antibiotics approved under these frameworks meaningfully address unmet clinical needs or improve patient outcomes. This project proposes a novel evaluative framework for antibiotic innovation that goes beyond approval counts to assess patient-centered benefit. We will (1) examine how major federal laws and FDA regulatory changes have impacted evidentiary standards for the approval of new antibiotics; and (2) determine the extent to which newly approved antibiotics meet previously unmet medical needs and improve patient-level outcomes relative to existing therapies. This study will generate essential evidence to guide future regulatory strategies and ensure meaningful innovation in antimicrobial drug development.
    Market Failures in the US Pharmaceutical Sector: The Case of Antibiotics
    Laura and John Arnold Foundation 20-05204Jan 1, 2021 - Feb 28, 2022
    Role: co-PI
    Description: High drug prices and misaligned economic incentives remain a challenge in the US healthcare system. Over the past four decades, federal statutes have shaped the pharmaceutical pricing and reimbursement landscape. The Hatch-Waxman Act (1984) expanded patent and market exclusivities; the Omnibus Budget Reconciliation Act (1990) established the Medicaid Drug Rebate Program; and the Medicare Modernization Act (2003) prohibited direct drug price negotiations under Medicare Part D. The GAIN Act (2012) created the Qualified Infectious Disease Product designation, granting additional exclusivity to antibiotics. These policies may inadvertently incentivize the approval of high-cost antibiotics with limited clinical value. The specific study aims are: Aim 1: To assess how market failures and regulatory loopholes impacted the development and FDA approval of antibiotics targeting unmet clinical needs; and Aim 2: To evaluate associations between antibiotic pricing, reimbursement policies, and the added clinical value of newly approved antibiotics versus existing therapies. As the largest healthcare payer, the U.S. federal government, through Medicare and Medicaid, absorbs the fiscal impact of these pricing dynamics. This project will generate critical insights to inform federal policy reforms, reimbursement models, and value-based antibiotic innovation.
    A multi-level evaluation of California’s New Medicaid Coverage for the Diabetes Prevention Program
    NIH/NIDDK 1R18DK122372-01A1Jul 27, 2020 - Jun 30, 2026
    Role: Site PI
    Description: Type 2 diabetes remains a leading cause of preventable morbidity, particularly among low-income populations. In response, California Senate Bill 97 (SB 97) mandated Medicaid coverage for the CDC-recognized Diabetes Prevention Program (DPP) beginning January 1, 2019. This natural experiment offers a unique opportunity to evaluate the real-world impact of a statewide DPP mandate. This is a multi-level, mixed-methods evaluation of SB 97 using electronic health record data from two largest healthcare systems in California, Kaiser Permanente Northern California and UCLA Health, as well as qualitative data from DPP suppliers, lifestyle coaches, and Medicaid participants. The Specific Aims are: (1) To assess the effectiveness of mandated DPP coverage for Medicaid beneficiaries with prediabetes on clinical outcomes, compared to a control cohort with private insurance from California Health Insurance Exchanges; (2) To model projected reductions in diabetes-related healthcare expenditures for Medicaid; and (3) To characterize barriers and facilitators to DPP uptake, retention, and success from the perspectives of DPP stakeholders. Study findings will inform whether Medicaid DPP coverage improves population health and is scalable and sustainable. This study will have implications for states considering similar mandates and will directly inform federal and state policymakers seeking to reduce diabetes risk in vulnerable populations.
    Shortages of Opioid Analgesics: Safety and Treatment Cost Implications in Surgical Patients
    NIH National Center for Advancing Translational Sciences -CTSI UL1 TR991872Jun 1, 2019 - May 31, 2020
    Role: PI
    Description: This study aims to evaluate the impact of opioid analgesic shortages on patient safety, opioid-related adverse events, and treatment costs in surgical patients. The findings provide perioperative physicians and other stakeholders with critical insights into the health impact and economic burden of opioid shortages.

    Collapse ORNG Applications 
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL. Blood Adv. 2025 Nov 25; 9(22):5837-5852. Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson S, Butte AJ. PMID: 40902085; PMCID: PMC12663514.
      View in: PubMed   Mentions:    Fields:    
    2. Advancing healthcare decision-making for the common good: a tribute to Professor Rovira Forns. Health Econ Policy Law. 2025 Jul; 20(3):225-232. Costa-Font J, Rodriguez-Monguio R. PMID: 40932247.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. A scoping review on generative AI and large language models in mitigating medication related harm. NPJ Digit Med. 2025 Mar 28; 8(1):182. Ong JCL, Chen MH, Ng N, Elangovan K, Tan NYT, Jin L, Xie Q, Ting DSW, Rodriguez-Monguio R, Bates DW, Liu N. PMID: 40155703; PMCID: PMC11953325.
      View in: PubMed   Mentions: 1  
    4. A Scoping Review on Generative AI and Large Language Models in Mitigating Medication Related Harm. npj Digital Medicine. 2025. Liu N, Ong J, Chen M, Ng N, Elangovan K, Ting Tan N, Jin L, Xie Q, Ting D, Rodriguez-Monguio R, and Bates D.
    5. The Association of Opioid Prescriptions to Children after Discharge from Surgery and New Opioid Prescription Fills in Family Members. J Pediatr. 2025 Feb 5:114505. doi: 10.1016/j.jpeds.2025.114505. Epub ahead of print. PMID: 39921119. 2025. Langnas E, Lin A, Luo Y, Rodriguez-Monguio R, Bicket M, Cairo S, De Vaan M, Chen CL.
    6. The Association of Opioid Prescriptions to Children after Discharge from Surgery and New Opioid Prescription Fills in Family Members. J Pediatr. 2025 Dec; 287:114505. Langnas E, Lin A, Luo Y, Rodriguez-Monguio R, Bicket M, Cairo S, De Vaan M, Chen CL. PMID: 39921119.
      View in: PubMed   Mentions: 1     Fields:    
    7. Causal effect estimation in survival analysis with high dimensional confounders. Biometrics. 2024 Oct 03; 80(4). Jiang F, Zhao G, Rodriguez-Monguio R, Ma Y. PMID: 39400258; PMCID: PMC11472547.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Healthcare expenditures for people with substance use disorders in drug courts compared to their peers in traditional courts. Drug Alcohol Depend Rep. 2024;12:100258. doi:10.1016/j.dadr.2024.100258. PMID: 39156655; PMCID: PMC11327541. 2024. Montgomery BW, Aldridge A, Drawbridge D, Packer I, Vincent GM, Rodriguez-Monguio R. .
    9. Healthcare expenditures for people with substance use disorders in drug courts compared to their peers in traditional courts. Drug Alcohol Depend Rep. 2024 Sep; 12:100258. Montgomery BW, Aldridge A, Drawbridge D, Packer I, Vincent GM, Rodriguez-Monguio R. PMID: 39156655; PMCID: PMC11327541.
      View in: PubMed   Mentions:
    10. Generic Entry and Effect of Market Competition on Outpatient Pharmacy Drug Prices. Journal of Generic Medicines 2024;20(2):69-76. doi.org/10.1177/17411343241248521. 2024. Mohammed J, Almutairi R, Seoane E, Brown L, Burnham T, Rakovski C, Rodriguez-Monguio R. .
    11. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022. Sci Rep. 2024 02 09; 14(1):3325. Seoane-Vazquez E, Rodriguez-Monguio R, Powers JH. PMID: 38336899; PMCID: PMC10858128.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas. Healthcare (Basel). 2023 Jun 15;11(12):1759. doi: 10.3390/healthcare11121759. PMID: 37372877. 2023. Rodriguez-Monguio R, Seoane-Vazquez E, Powers J .
    13. A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas. Healthcare (Basel). 2023 Jun 15; 11(12). Rodriguez-Monguio R, Seoane-Vazquez E, Powers JH. PMID: 37372877; PMCID: PMC10298669.
      View in: PubMed   Mentions:
    14. Analysis of the Gene Therapies Authorized by the United States Food and Drug Administration and the European Medicines Agency. Med Care. 2023 07 01; 61(7):438-447. Ghanem B, Seoane-Vazquez E, Brown L, Rodriguez-Monguio R. PMID: 36884030.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Safety implications of concomitant administration of antidepressants and opioid analgesics in surgical patients. Expert Opin Drug Saf. 2023 Jan-Jun; 22(6):477-484. Rodriguez-Monguio R, Lun Z, Dickinson DT, Do C, Hyland B, Kocharyan E, Liu L, Steinman MA. PMID: 36803512; PMCID: PMC11059447.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Disentangling the Cost of Orphan Drugs Marketed in the United States. Healthcare (Basel). 2023 Feb 13; 11(4). Althobaiti H, Seoane-Vazquez E, Brown LM, Fleming ML, Rodriguez-Monguio R. PMID: 36833091; PMCID: PMC9957503.
      View in: PubMed   Mentions: 5  
    17. Inpatient administration of opioids and risk for post-operative ileus in older adults. J Opioid Manag. 2022 Jul-Aug; 18(4):317-325. Rodriguez-Monguio R, Berkley E, Mendoza E, Miller K, Selim S, Trac C, Lun Z, Reisner L. PMID: 36052930.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Opioid prescribing practices at hospital discharge for surgical patients before and after the Centers for Disease Control and Prevention's 2016 opioid prescribing guideline. BMC Anesthesiol. 2022 05 11; 22(1):141. Langnas E, Bishara A, Croci R, Rodriguez-Monguio R, Wick EC, Chen CL, Guan Z. PMID: 35546657; PMCID: PMC9097447.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. The American Public Health Association Endorses Single-Payer Health System Reform. Med Care. 2022 06 01; 60(6):397-401. King B, Spadaro A, Schiff G, Rodriguez-Monguio R, Jordan AO, Flaherty L, Lee WC, Zito J, Fein O, American Public Health Association, Medical Care Section. PMID: 35471488.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Postoperative Respiratory Events in Surgical Patients Exposed to Opioid Analgesic Shortages Compared to Fully Matched Patients Non-exposed to Shortages. Drug Saf. 2022 04; 45(4):359-367. Rodriguez-Monguio R, Lun Z, Bongiovanni T, Chen CL, Seoane-Vazquez E. PMID: 35298825.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. The association of multimodal analgesia and high-risk opioid discharge prescriptions in opioid-naive surgical patients. Perioper Med (Lond). 2021 Dec 15; 10(1):60. Langnas E, Rodriguez-Monguio R, Luo Y, Croci R, Dudley RA, Chen CL. PMID: 34906217; PMCID: PMC8672612.
      View in: PubMed   Mentions: 1  
    22. Hospital admission medication reconciliation in high-risk prescription opioid users. Res Social Adm Pharm. 2022 08; 18(8):3379-3385. Rodriguez-Monguio R, Lun Z, Kehr K, Agustin JP, San Agustin-Nordmeier K, Huynh C, Reisner L. PMID: 34972641.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Enhanced recovery after surgery protocol and postoperative opioid prescribing for cesarean delivery: an interrupted time series analysis. Perioper Med (Lond). 2021 Nov 15; 10(1):38. Langnas EM, Matthay ZA, Lin A, Harbell MW, Croci R, Rodriguez-Monguio R, Chen CL. PMID: 34775985; PMCID: PMC8591895.
      View in: PubMed   Mentions: 1  
    24. Substance use treatment services utilization and outcomes among probationers in drug courts compared to a matched cohort of probationers in traditional courts. Am J Addict. 2021 09; 30(5):505-513. Rodriguez-Monguio R, Montgomery B, Drawbridge D, Packer I, Vincent GM. PMID: 34414632.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece? PLoS One. 2021; 16(3):e0249274. Rodriguez-Monguio R, Naveed M, Seoane-Vazquez E. PMID: 33788898; PMCID: PMC8011730.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis. Infect Control Hosp Epidemiol. 2021 09; 42(9):1090-1097. Trinh TD, Strnad L, Damon L, Dzundza JH, Graff LR, Griffith LM, Hilts-Horeczko A, Olin R, Shenoy S, DeVoe C, Wang L, Rodriguez-Monguio R, Gu TM, Hampton SR, Macapinlac BAC, Yang K, Doernberg SB. PMID: 33487182; PMCID: PMC8459315.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    27. Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology. 2021 Mar; 149:168-173. Chu CE, Law L, Zuniga K, Lin TK, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, Carroll PR, Pruthi RS, Meng MV, Chen LL, Porten SP. PMID: 33278460.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Perioperative Prescribing Practices of Extended-Release Opioids in Noncancer Surgical Patients, 2015-2018. Anesth Analg. 2020 10; 131(4):1249-1259. Rodriguez-Monguio R, Naveed M, Croci R, Gross K, Langnas E, Chen CL, Seoane-Vazquez E. PMID: 32925346.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Long-Term Trends in Postoperative Opioid Prescribing, 1994 to 2014. J Am Acad Orthop Surg Glob Res Rev. 2020 01; 4(1). Chen CL, Jeffery MM, Krebs EE, Thiels CA, Schumacher MA, Schwartz AJ, Thombley R, Finlayson E, Rodriguez-Monguio R, Ward D, Dudley RA. PMID: 32159068; PMCID: PMC7028788.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Using a Machine Learning System to Identify and Prevent Medication Prescribing Errors: A Clinical and Cost Analysis Evaluation. Jt Comm J Qual Patient Saf. 2020 01; 46(1):3-10. Rozenblum R, Rodriguez-Monguio R, Volk LA, Forsythe KJ, Myers S, McGurrin M, Williams DH, Bates DW, Schiff G, Seoane-Vazquez E. PMID: 31786147.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    31. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost. Hum Gene Ther Clin Dev. 2019 09; 30(3):102-113. Shukla V, Seoane-Vazquez E, Fawaz S, Brown L, Rodriguez-Monguio R. PMID: 30968714.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    32. Erratum: Gender Differences in Mental Health and Substance Use Disorders and Related Healthcare Services Utilization. Am J Addict. 2019 Jul; 28(4):324. Brand E, Rodriguez-Monguio R, Volber R. PMID: 31233262.
      View in: PubMed   Mentions:    Fields:    
    33. The Landscape of Cellular and Gene Therapy Products: Cost, Approvals, and Discontinuations. Hum Gene Ther Clin Dev. 2019 Sep;30(3):102-113. doi: 10.1089/humc.2018.201. Epub 2019 Jul 16. 2019. Shukla V, Seoane E, Souhiela F, Lawrence B, Rodriguez-Monguio R.
    34. Innovation and competition in advanced therapy medicinal products. EMBO Mol Med. 2019 03; 11(3). Seoane-Vazquez E, Shukla V, Rodriguez-Monguio R. PMID: 30770338; PMCID: PMC6404110.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    35. Gender differences in mental health and substance use disorders and related healthcare services utilization. Am J Addict. 2019 01; 28(1):9-15. Brand E, Rodriguez-Monguio R, Volber R. PMID: 30536669.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    36. Incorporating medication indications into the prescribing process. Am J Health Syst Pharm. 2018 06 01; 75(11):774-783. Kron K, Myers S, Volk L, Nathan A, Neri P, Salazar A, Amato MG, Wright A, Karmiy S, McCord S, Seoane-Vazquez E, Eguale T, Rodriguez-Monguio R, Bates DW, Schiff G. PMID: 29674327.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    37. Driving and riding under the influence of recent marijuana use: Risk factors among a racially diverse sample of young adults. J Ethn Subst Abuse. 2019 Oct-Dec; 18(4):594-612. Whitehill JM, Rodriguez-Monguio R, Doucette M, Flom E. PMID: 29432083.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    38. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Serv Res. 2018 02 01; 18(1):78. Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 29391064; PMCID: PMC5796582.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    39. The Economic Burden of Pathological Gambling and Co-occurring Mental Health and Substance Use Disorders. J Addict Med. 2018 Jan/Feb; 12(1):53-60. Rodriguez-Monguio R, Brand E, Volberg R. PMID: 29068825.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharm J. 2018 Feb; 26(2):238-243. Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 30166922; PMCID: PMC6111194.
      View in: PubMed   Mentions: 10  
    41. The patient-centered medical home model: healthcare services utilization and cost for non-elderly adults with mental illness. J Ment Health. 2018 Dec; 27(6):574-582. Bowdoin JJ, Rodriguez-Monguio R, Puleo E, Keller D, Roche J. PMID: 28990831.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Comorbid pathological gambling, mental health, and substance use disorders: Health-care services provision by clinician specialty. J Behav Addict. 2017 Sep 01; 6(3):406-415. Rodriguez-Monguio R, Errea M, Volberg R. PMID: 28856904; PMCID: PMC5700728.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    43. Exploring the potential for using drug indications to prevent look-alike and sound-alike drug errors. Expert Opin Drug Saf. 2017 Oct; 16(10):1103-1109. Seoane-Vazquez E, Rodriguez-Monguio R, Alqahtani S, Schiff G. PMID: 28724335.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. Opioid Prescription Drug Use and Expenditures in US Outpatient Physician Offices: Evidence from Two Nationally Representative Surveys. Cancer Ther Oncol Int J. 2017; 3(3). Qureshi ZP, Haider MR, Rodriguez-Monguio R, Wooten NR, Nikitin RV, Ball S, Barth K, Elk R, Horner R, Bennett C. PMID: 28845476; PMCID: PMC5568124.
      View in: PubMed   Mentions: 2  
    45. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 Mar; 6(2):97-108. Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. PMID: 28118731.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS. Int J Technol Assess Health Care. 2016 Jan; 32(6):385-392. Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 28065194.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs? Orphanet J Rare Dis. 2017 01 05; 12(1):1. Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. PMID: 28057032; PMCID: PMC5217554.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    48. Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses. Curr Med Res Opin. 2016 12; 32(12):1969-1974. Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. PMID: 27603119.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    49. Associations between the patient-centered medical home and preventive care and healthcare quality for non-elderly adults with mental illness: A surveillance study analysis. BMC Health Serv Res. 2016 08 24; 16(1):434. Bowdoin JJ, Rodriguez-Monguio R, Puleo E, Keller D, Roche J. PMID: 27557785; PMCID: PMC4997759.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States. Curr Med Res Opin. 2016 11; 32(11):1783-1788. Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. PMID: 27359262.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    51. Response to letter to the editor regarding Alqahtani et al. Article on priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiol Drug Saf. 2016 06; 25(6):745-6. Seoane-Vazquez E, Rodriguez-Monguio R, Alqahtani S. PMID: 27245860.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Health Information Technologies: Which Nursing Homes Adopted Them? J Am Med Dir Assoc. 2016 05 01; 17(5):441-7. Zhang N, Lu SF, Xu B, Wu B, Rodriguez-Monguio R, Gurwitz J. PMID: 27107160.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    53. Are Obese Residents More Likely to Be Admitted to Nursing Homes That Have More Deficiencies in Care? J Am Geriatr Soc. 2016 05; 64(5):1085-90. Zhang N, Rodriguez-Monguio R, Barenberg A, Gurwitz J. PMID: 27225360.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    54. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs. Clin Drug Investig. 2016 Apr; 36(4):281-92. Seoane-Vazquez E, Rodriguez-Monguio R, Hansen R. PMID: 26818406.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    55. Gambling involvement indicative of underlying behavioral and mental health disorders. Am J Addict. 2016 Mar; 25(2):160-72. Okunna NC, Rodriguez-Monguio R, Smelson DA, Poudel KC, Volberg R. PMID: 26871884.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    56. FDA safety actions for antidiabetic drugs marketed in the US, 1980-2015. Int J Risk Saf Med. 2016; 28(4):197-211. Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 28582876.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS One. 2015; 10(10):e0140708. Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. PMID: 26469277; PMCID: PMC4607470.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    58. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis. Expert Rev Pharmacoecon Outcomes Res. 2016; 16(1):127-34. Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. PMID: 26174631.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Response to Letter to the Editor: Regarding the Bulzacchelli et al. Article on Injury During U.S. Army Basic Combat Training. Am J Prev Med. 2015 Jul; 49(1):e3-5. Bulzacchelli MT, Sulsky SI, Rodriguez-Monguio R, Karlsson LH, Hill LT. PMID: 26094237.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Capsule commentary on Goetz et al., The effect of charge display on cost of care and physician practice behaviors: a systematic review. J Gen Intern Med. 2015 Jun; 30(6):834. Rodriguez-Monguio R. PMID: 25749883; PMCID: PMC4441651.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiol Drug Saf. 2015 Jul; 24(7):709-15. Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T. PMID: 26013294.
      View in: PubMed   Mentions: 15     Fields:    
    62. Methodological challenges of using U.S. Army administrative data to identify a cohort of basic combat trainees and descriptive analysis of trends in characteristics that are potential risk factors for training-related injury. Mil Med. 2014 Dec; 179(12):1487-96. Sulsky SI, Karlsson LH, Bulzacchelli MT, Luippold RS, Rodriguez-Monguio R, Bulathsinhala L, Hill OT. PMID: 25469973.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    63. Injury during U.S. Army basic combat training: a systematic review of risk factor studies. Am J Prev Med. 2014 Dec; 47(6):813-22. Bulzacchelli MT, Sulsky SI, Rodriguez-Monguio R, Karlsson LH, Hill MO. PMID: 25455122.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    64. Medicaid provisions and the US mental health industry composition. J Ment Health. 2014 Dec; 23(6):312-6. Pellegrini LC, Rodriguez-Monguio R. PMID: 25180818.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. The US healthcare workforce and the labor market effect on healthcare spending and health outcomes. Int J Health Care Finance Econ. 2014 Jun; 14(2):127-41. Pellegrini LC, Rodriguez-Monguio R, Qian J. PMID: 24652416.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    66. Examination of risk evaluation and mitigation strategies and drug safety in the US. Res Social Adm Pharm. 2014 Jan-Feb; 10(1):232-8. Rodriguez-Monguio R, Spielberger K, Seoane-Vazquez E. PMID: 23611865.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    67. Healthcare cost of type 1 diabetes mellitus in new-onset children in a hospital compared to an outpatient setting. BMC Pediatr. 2013 Apr 15; 13:55. Jasinski CF, Rodriguez-Monguio R, Tonyushkina K, Allen H. PMID: 23587308; PMCID: PMC3637533.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    68. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies. BMC Health Serv Res. 2013 Jan 22; 13:27. Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M. PMID: 23339419; PMCID: PMC3582490.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    69. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J Law Med Ethics. 2013; 41(3):688-96. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. PMID: 24088160.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    70. Racial disparities in the risk of developing obesity-related diseases: a cross-sectional study. Ethn Dis. 2012; 22(3):308-16. Zhang H, Rodriguez-Monguio R. PMID: 22870574.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    71. Comparing the cost of community pharmacy and mail-order pharmacy in a US retirement system. Int J Health Plann Manage. 2012 Jan-Mar; 27(1):e41-50. Visaria J, Seoane-Vazquez E, Szeinbach SL, Rodriguez-Monguio R. PMID: 21638311.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):772-7. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. PMID: 21574210.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansPHPublic Health
    73. Access to essential drugs in Guyana: a public health challenge. Int J Health Plann Manage. 2010 Jan-Mar; 25(1):2-16. Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 18536003.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    74. Patent life of antiretroviral drugs approved in the US from 1987 to 2007. AIDS Care. 2009 Jun; 21(6):760-8. Rodriguez-Monguio R, Seoane-Vazquez E. PMID: 19499381.
      View in: PubMed   Mentions: 2     Fields:    
    75. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents. Food Drug Law J. 2009; 64(1):171-81. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Beyer A, Visaria J. PMID: 19998745.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    76. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008 Dec 16; 3:33. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. PMID: 19087348; PMCID: PMC2631478.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    77. Endoscopy-related infection: relic of the past? Curr Opin Infect Dis. 2008 Aug; 21(4):362-6. Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 18594287.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    78. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy. BMC Health Serv Res. 2007 Jul 30; 7:122. Valluri S, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL. PMID: 17663768; PMCID: PMC1950867.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    79. Endoscopy-related infections and toxic reactions: an international comparison. Endoscopy. 2007 Aug; 39(8):742-6. Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J, Carlson A. PMID: 17583855.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    80. Negotiating antiretroviral drug prices: the experience of the Andean countries. Health Policy Plan. 2007 Mar; 22(2):63-72. Seoane-Vazquez E, Rodriguez-Monguio R. PMID: 17299024.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    81. Exogenous endoscopy-related infections, pseudo-infections, and toxic reactions: clinical and economic burden. Curr Med Res Opin. 2006 Oct; 22(10):2007-21. Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J, Carlson A. PMID: 17022860.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    82. Analysis of the World Bank's pharmaceutical lending. Health Policy. 2007 Apr; 81(1):102-16. Rodríguez-Monguió R, Rovira J, Seoane-Vázquez E. PMID: 16824640.
      View in: PubMed   Mentions:    Fields:    
    83. Healthcare rationing in Spain: framework, descriptive analysis and consequences. Pharmacoeconomics. 2006; 24(6):537-48. Rodríguez-Monguió R, Antoñanzas Villar F. PMID: 16761902.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    84. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003; 21(9):623-50. Rodríguez-Monguió R, Otero MJ, Rovira J. PMID: 12807365.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    Rosa's Networks
    Concepts (281)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.